Lipoatrophy is a highly prevalent complication of antiretroviral (ARV) therapy, associated with decreased quality of life, disincentive for adherence to antiretroviral therapy, as well as possibly an increased risk of coronary artery disease. Lipoatrophy has been shown to correlate with mitochondrial abnormalities, mainly with histological abnormalities and decreased subcutaneous fat mtDNA content, but the exact mechanism of this dysfunction and its importance in the pathogenesis of lipoatrophy remain unclear. Recent work from our group suggested an association between oxidative stress and lipoatrophy. Reactive oxygen species (ROS) contribute to oxidative stress and are produced principally by the mitochondria during oxidative phosphorylation (OXPHOS). ROS damages mitochondrial DNA (mtDNA), lipids, and proteins leading to a decrease in expression of mtDNA related products involved in OXPHOS, and subsequent decrease in ATP synthesis. Whether the finding of increased oxidative stress represents the consequence of or the cause of this mitochondrial dysfunction is unclear. Our long-range goal is to understand the role played by mitochondria in the development and reversal of lipoatrophy. We hypothesize that the initiation of nucleoside analogue reverse transcriptase inhibitor (NRTI)-containing therapy leads to alteration in mtDNA synthesis which will be assessed by a decrease in mtDNA levels and a resultant decrease in synthesis of mtDNA-encoded respiratory chain subunits with ultimately a defect in OXPHOS. The latter will in turn lead to an increase in fat apoptosis and in oxidation of mitochondria and lipids. This will be assessed in longitudinal studies of subjects who are starting their first NRTI-containing antiretroviral regimen. In addition, we propose to study 2 types of interventions to reduce lipoatrophy and facilitate our understanding of the role of mitochondrial recovery in the regression of lipoatrophy: (1) decreasing exposure to inducers of lipoatrophy by substitution of the mitochondrial friendly NRTI tenofovir, for d4T, and (2) use of undine supplementation. We hypothesize that both interventions will be able to replete mtDNA content in tissues, followed by improvement of mitochondrial function and decrease fat apoptosis and oxidative damage, with subsequent increase in subcutaneous fat. Blood, skeletal muscle, and subcutaneous fat biopsies will be obtained from patients prior to, and 24, and 48 weeks after the clinical intervention, to measure changes in mtDNA content, mitochondrial functional assays, oxidative damage biomarkers, and fat apoptosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI060484-05
Application #
7576709
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Brobst, Susan W
Project Start
2005-03-15
Project End
2011-02-28
Budget Start
2009-03-01
Budget End
2011-02-28
Support Year
5
Fiscal Year
2009
Total Cost
$303,205
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Ross, Allison C; Hileman, Corrilynn O; Brown, Todd T et al. (2012) Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials 13:212-21
McComsey, Grace A; O'Riordan, MaryAnn; Choi, Julia et al. (2012) Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther 17:347-53
Tungsiripat, Marisa; El-Bejjani, Dalia; Rizk, Nesrine et al. (2012) Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy. J AIDS Clin Res 3:174
Tungsiripat, Marisa; El-Bejjani, Dalia; Rizk, Nesrine et al. (2011) Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 27:295-302
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Tungsiripat, Marisa; Bejjani, Dalia El; Rizk, Nesrine et al. (2010) Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24:1291-8
Tungsiripat, Marisa; O'Riordan, Mary Ann; Storer, Norma et al. (2009) Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials 10:314-9
Ross, Allison C; Armentrout, Rachel; O'Riordan, Mary Ann et al. (2008) Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 49:499-506
McComsey, G A; Lo Re 3rd, V; O'Riordan, M et al. (2008) Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 46:1290-6

Showing the most recent 10 out of 11 publications